Identification of a 16-MTGs Prognostic Signature in Diffuse Large B-Cell Lymphoma
Background. Diffuse large B-cell lymphoma (DLBCL) is one of the largest lymphoma subcategories. Usually, 50%–70% of DLBCL patients can be cured by the standard treatment. But, at least one third have bad prognosis. Based on this situation, the research on DLBCL therapy strategy is still indispensabl...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Analytical Cellular Pathology |
| Online Access: | http://dx.doi.org/10.1155/2024/4619644 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|